In Brief: Bayer's Precose
Executive Summary
Bayer's Precose: Endocrinologic & Metabolic Drugs Advisory Committee will discuss NDA 20-482 for Bayer's acarbose for the treatment of non-insulin dependent diabetes mellitus on June 1. The E&M advisory committee recommended not to approve the product at a meeting in 1991. Bayer's U.S. subsidiary resubmitted the NDA in November. The meeting will take place at the Holiday Inn, 8777 Georgia Ave., Silver Spring, Md., beginning at 8 a.m...